Black Diamond Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Black Diamond Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($8.50M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($10.56M) | Aug 7, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($10.56M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | $56.54M | May 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | $56.54M | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | $56.54M | Nov 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($15.56M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($19.91M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($19.91M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($18.23M) | May 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($18.23M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($18.23M) | Nov 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($23.01M) | Nov 5, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($19.15M) | Aug 6, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($19.15M) | Nov 5, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($20.88M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($20.88M) | Aug 6, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($20.88M) | Nov 5, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($21.65M) | Nov 6, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($22.93M) | Aug 11, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($10.98M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($13.42M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | $54.53M | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($18.13M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($22.13M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($20.25M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($24.01M) | Nov 5, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($20.03M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($21.56M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($22.12M) | Nov 6, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($23.17M) | Aug 11, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($25.68M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($35.36M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($34.72M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($30.71M) | May 11, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($18.48M) | Nov 8, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($15.03M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($12.88M) | May 7, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($8.15M) | Nov 10, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($7.00M) | Aug 11, 2020 |